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Abstract
The progression of prostate cancers (PCs) to locally invasive, androgen-independent and metastatic disease states is
generally associated with treatment resistance and disease relapse. The present study was undertaken to establish the
possibility of using a combination of specific oncogenic products, including epidermal growth factor receptor (EGFR), pAkt,
nuclear factor-kappaB (NF-kB) and macrophage inhibitory cytokine-1 (MIC-1) as biomarkers and therapeutic targets for
optimizing the management of patients with localized PC at earlier disease stages. The immunohistochemical and
immunofluorescence data have revealed that the expression levels of EGFR, Ser473-pAkt, NF-kB p65 and MIC-1 proteins were
significantly enhanced in the same subset of 76 cases of prostatic adenocarcinoma specimens during the disease
progression and these biomarkers were expressed in a small subpopulation of CD133+ PC cells and the bulk tumor mass of
CD1332 PC cells. Importantly, all of these biomarkers were also overexpressed in 80–100% of 30 PC metastasis bone tissue
specimens. Moreover, the results have indicated that the EGF-EGFR signaling pathway can provide critical functions for the
self-renewal of side population (SP) cells endowed with stem cell-like features from highly invasive WPE1-NB26 cells. Of
therapeutic interest, the targeting of EGFR, pAkt, NF-kB or MIC-1 was also effective at suppressing the basal and EGF-
promoted prostasphere formation by SP WPE1-NB26 cells, inducing disintegration of SP cell-derived prostaspheres and
decreasing the viability of SP and non-SP WPE1-NB26 cell fractions. Also, the targeting of these oncogenic products induced
the caspase-dependent apoptosis in chemoresistant SP WPE1-NB26 cells and enhanced their sensibility to the cytotoxic
effects induced by docetaxel. These findings suggest that the combined use of EGFR, pAkt, NF-kB and/or MIC-1 may
represent promising strategies for improving the accuracy of current diagnostic and prognostic methods and efficacy of
treatments of PC patients in considering the disease heterogeneity, thereby preventing PC progression to metastatic and
lethal disease states.
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Introduction
Prostate cancer (PC) remains among the most frequently
diagnosed solid tumors in men and the metastatic PC forms still
represent the second leading cause of cancer-related death [1]–[5].
Important advances in past few years have led to an earlier
diagnosis and effective therapeutic intervention by radical
prostatectomy and/or radiation therapy for the patients with
low-grade and organ-confined PCs [1], [4], [6], [7]. Disease
progression to locally advanced, metastatic and castration-resistant
prostate cancers (CRPCs) is associated with treatment resistance
and disease relapse [1], [4], [6]. Although current anti-hormonal
and chemotherapeutic regimens for highly invasive and metastatic
PCs generally have improved the quality of life, these therapies are
only palliative and culminate in the death of most patients after
about 12–19 months following diagnosis [1], [4], [6].
Numerous studies have been performed to establish the
etiopathological causes of PCs. The extrinsic and intrinsic factors
pre-disposing to PC development include intense oxidative stress,
inflammatory atrophies and fibrosis associated with severe tissue
injuries, hormonal deregulation and more particularly with
advancing age [8]–[13]. Initiation and progression of PC is
generally characterized by a down-regulation of diverse tumor
suppressor gene products, including phosphatase tensin homolog
deleted on chromosome 10 (PTEN) and p53, combined with an
up-regulation of the expression and/or activity of numerous
oncogenic signaling elements in PC cells [4], [13], [14]. The
interplay of complex signaling networks of distinct tumorigenic
pathways initiated by hormones, growth factors, cytokines and
chemokines through their cognate receptors is typically involved in
the PC progression to locally advanced and metastatic disease [4],
[10], [11], [13], [15]. Among the frequent deregulated gene
products, the enhanced expression and activation of diverse
receptor tyrosine kinases, including epidermal growth factor
receptor (EGFR), during the epithelial-mesenchymal transition
process may lead to the sustained activation of mitogen-activated
protein kinases, phosphatidylinositol 39-kinase (PI3K)/Akt, nuc-
lear factor kappa-B (NF-kB) and macrophage inhibitory cytokine-
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1 (MIC-1) [4], [13], [14], [16]–[32]. These oncogenic products
may cooperate to promote the sustained growth, survival, invasion
and metastasis of PC cells as well as for their acquisition of
androgen-independent (AI) and chemoresistant phenotypes, treat-
ment resistance and disease recurrence [4], [13]–[16], [18]–[21],
[23], [25]–[27], [30]–[39].
In addition, recent accumulating lines of experimental evidence
have also revealed that PC stem/progenitor cells, also designated
as PC- and metastasis-initiating cells, expressing stem cell-like
markers such as CD133, CD44high, aldehyde dehydrogense
‘‘ALDHhigh’’ and/or CXC chemokine receptor 4 can provide
critical functions in prostate carcinogenesis, metastases at distant
sites and tumor re-growth and disease recurrence after treatment
initiation [4], [10], [13], [14], [40]–[58]. It has been shown that
highly tumorigenic PC stem/progenitor cells were able to give rise
in vitro and in vivo to the bulk mass of differentiated PC cells
expressing secretory luminal phenotypes, including androgen
receptor and prostatic acid phosphatase, and reconstitute the
tumors in vivo with a histological architecture of a Gleason grade
comparable to the patient’s original tumors [13], [40]–[45], [47],
[48], [53]. It has also been observed that the PC stem/progenitor
cells, including side population (SP) isolated from PC cells by using
Hoechst dye efflux technique, which possess an AI phenotype and
express high levels of ATP-binding cassette (ABC) multidrug
transporters such as ABCG2, were also more resistant than their
differentiated progenies and non-SP cells to the anti-hormonal and
chemotherapeutic treatments [13], [14], [50]–[52], [59]. In spite
of these advances, additional studies are required to validate
distinct molecular biomarkers and therapeutic targets in PC stem/
progenitor cells and their progenies that could be used in
combination for optimizing the therapeutic management of PC
patients at earlier disease stages.
The present investigation was undertaken to determine the clinical
relevance of using a combination of multiple deregulated oncogenic
products, including EGFR, the phosphorylated form of Akt, NF-kB
p65 and MIC-1 as molecular biomarkers to predict the risk of PC
progression to locally advanced tumor and therapeutic targets to
eradicate the total PC cell mass. Therefore, the immunohistochem-
ical analyses of the expression levels and co-localization patterns of
these proteins were made on the same panel of PC tissues and
compared with non-malignant adjacent tissues and normal prostatic
tissue specimens. Moreover, the prostasphere-forming and -disinte-
gration assays and viability tests with SP cells endowed with stem cell-
like properties and the non-SP cell fraction from the highly
tumorigenic and invasive WPE1-NB26 cell line were performed
with or without exogenous EGF in the absence or presence of the
specific inhibitory agents of these oncogenic products. Overall, the
results have supported the benefits of combining these oncogenic
products as molecular biomarkers and therapeutic targets for
improving the accuracy of diagnostic and prognostic methods and
the efficacy of treatments of PC patients at earlier disease stages.
Materials and Methods
Materials
The human WPE1-NB26 cell line was originally obtained from
American Type Culture Collection (Manassas, VA). The parental
WPE1-NB26 cells were routinely maintained in keratinocyte serum-
free medium (SFM) supplemented with antibiotics (100 UI/ml
penicillin-100 mg/ml streptomycin), L-glutamine, bovine pituitary
extract and epidermal growth factor (EGF) according to the
manufacturer’s instructions in a 37uC incubator supplied with 5%
CO2. Keratinocyte-SFM, MitoTracker Red CMXRos dye and all
other culture materials were from Life Technologies (Carlsbad,
CA). Docetaxel, partenolide, Akt inhibitor VIII, and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were
purchased from Sigma-Aldrich (St. Louis, MO), LY294002 from
Calbiochem Corp (San Diego, CA) and gefitinib came from LC
laboratory (Woburn, MA). The rabbit polyclonal anti-CD133
antibody (H-284), mouse monoclonal anti-CD44 (HCAM, F-4)
antibody, rabbit polyclonal anti-ABCG2 antibody (B-25), rabbit
polyclonal anti-EGFR antibody (1005), goat polyclonal anti-
Tyr1173-phospho-EGFR antibody (1173) recognizing the EGFR
form phosphorylated at tyrosine 1173 and rabbit polyclonal anti-
NF-kB p65 protein subunit (C-20) were purchased from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). The mouse monoclonal anti-b-
actin antibody (clone AC-15) was provided by Sigma-Aldrich (St-
Louis, MO, USA) and the rabbit monoclonal anti-Ser473-pAkt
antibody (D9E) from Cell Signaling Technology, Inc. The rabbit
polyclonal antibody directed against the cleaved caspase-9 fragment
was purchased from Cell Signaling Technology (Danvers, MA,
U.S.A.) and mouse monoclonal anti-cytochrome c (6H2) antibody
provided by Santa Cruz Biotechnology, Inc (Santa Cruz, CA, U.S.A.).
Rabbit polyclonal anti-MIC-1 antibody was generated in our
laboratory against the C-terminal amino acid region of the mature
MIC-1 protein as previously described [27], [29]. The phycoerythrin-
conjugated monoclonal anti-CD133/2 antibody (293C3) was pur-
chased from Miltenyi Biotec. Inc. and employed according to the
manufacturer’s instructions. The Vectastain avidin-biotin complex
‘‘ABC’’ method peroxidase kit and 3,39-diaminobenzidine ‘‘DAB’’
substrate kit for the immunohistochemical staining were purchased
from Vector Laboratories (Burlingame, CA).
Immunohistochemical and double-
immunohistofluorescence analyses
Immunohistochemical studies on the expression levels and
cellular localization of EGFR, Ser473-pAkt, NF-kB p65 and MIC-
1 proteins in non-malignant and malignant prostate tissues were
carried out on prostate tissue microarrays made from formalin-
fixed and paraffin-embedded tissues purchased from Biomax Inc.
(Rockville, Maryland, USA) as previously described. The analyzed
tissue specimens include the PR954 tissue microarray slide
containing duplicate cores from 36 cases of patients with primary
prostatic adenocarcinoma (Gleason scores: 6–10; stages T2–T4)
and the corresponding matched non-malignant adjacent tissues
from the same patients, and PR483 tissue microarray slide
containing one core from 40 cases of patients with primary
prostatic adenocarcinoma (Gleason scores: 6–10; stages T2–T4)
and 8 normal prostate tissues from autopsy used as controls. In
addition, the expression of all of biomarkers was also analyzed in
30 bone metastasis tissues from PC patients (Gleason scores: 6–10)
(TriStar Technology Group, LLC, U.S.A.). The technique used
for immunohistostaining has been previously described [36], [38],
[52]. Briefly, the tissue sections were deparaffinized with EZ-
DeWaxTM (Bio Genex, San Ramon, CA) and rehydrated using
graded ethanol solutions. After washing the slides 3 times with
phosphate buffer saline (PBS) for 5 min, tissue sections were
submerged in microwave antigen retrieval solution consisting of
0.01 M citrate buffer pH 6.0 and subjected to microwave
irradiation 3 times during 3 min. The nonspecific immunostaining
was blocked in diluted vectastain normal horse serum (Vector
‘‘ABC’’ kit) for 10 min and the slides were then incubated with
primary anti-EGFR, -Ser473-pAkt, -NF-kB p65 protein subunit or
-MIC-1 antibody in a humidified chamber overnight at 4uC. After
washing with PBS, the slides were incubated with biotinylated
universal secondary antibody for 30 min and rewashed with PBS.
Endogenous peroxidase activity was quenched using 0.3%
hydrogen peroxide in methanol:PBS (1:1) for 10 min. After an
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additional wash, the slides were incubated with ABC vectastain
solution for 30 min. The tissue sections were submerged in a
staining solution containing 3,39-diaminobenzidine ‘‘DAB’’ sub-
strate as indicated in the manufacturer’s instructions and rinsed 3
times in water. A reddish-brown color precipitate observed on
tissue sections indicates a positive immunoreactivity with the tested
primary antibody. The slides were counterstained with hematoxy-
lin, dehydrated and permanently mounted with vectamount
permanent mounting media (Vector Laboratories). Images that
were captured on a Nikon Eclipse E400 light microscope (Nikon
Corporation, Tokyo, Japan) at different magnifications are
representative of analyzed samples.
For each tissue section, the intensity of immunoreactivity for
EGFR, Ser473-pAkt, NF-kB p65 or MIC-1 protein was semi-
quantitatively graded by a urologic pathologist (Dr. Johansson) on a
0 to +3 scale (0=no staining, 1+=week staining, 2+=moderate
staining, and 3+=strong staining). The percentage of PC cells positive
for each biomarker analyzed within a given tissue core was also scored
on a 1 to 4 scale (1=0–25% positive PC cells, 2=26–50% positive
cells, 3=51–75% positive cells, and 4=76–100% positive cells). The
score of the staining intensity and the percentage of immunoreactive
PC cells were then multiplied to obtain a composite score ranging
from 0 to 12. The staining intensity of different tested proteins in
prostate adenocarcinoma samples was scored and compared to the
normal prostate tissues, and the value was considered enhanced if the
staining intensity was higher by one or more points.
In addition, the double-immunohistofluorescence analyses of
the co-localization of stem cell-like marker, CD133 antigen
(prominin-1) with unphosphorylated EGFR or its activated
Tyr1173p-EGFR phosphorylated form, Ser473-pAkt, NF-kB p65
or MIC-1 were also carried out on deparaffinized and rehydrated
non-malignant and malignant human prostatic tissue specimens
from the patients obtained from UNMC’s tissue bank as previously
reported [52], [60]. The tissue slides were blocked in the presence
of 10% goat serum for 30 min followed by incubation with the
phycoerythrin-conjugated anti-CD133 antibody plus anti-EGFR,
anti-Tyr1173-pEGFR, anti-Ser473-pAkt, anti-NF-kB p65 or anti-
MIC-1 antibody for 2 h. The slides were washed twice with PBS
and processed for immunofluorescent detection as described below
for the confocal microscopic analyses of fixed cells.
Isolation of the SP and non-SP cell fractions and CD133+
PC cell subpopulation from human tumorigenic and
invasive WPE1-NB26 cell line by flow cytometry
The parental WPE1-NB26 cells (16106 cells/mL) were stained
with Hoechst buffer containing a final concentration of 2 mg/mL
fluorescent Hoechst dye at 37uC for 2 h. The small subpopulations
of SP and non-SP cells were isolated by fluorescence-activated cell
sorting (FACS) as previously described [52], [60], [61]. The analyses
and sorting of the viable SP and non-SP cell fractions were done
using a FACS Aria flow cytometer with a DIVA software (Becton
Dickinson Biosciences). The SP and non-SP cell fractions were
collected after FACS and the expression level of the CD133 stem
cell-like marker without apparent further phenotypic and differen-
tiation changes in these two cultured cell subpopulations was
obtained by maintaining the cells in serum-free keratinocyte culture
medium containing exogenous EGF (10 ng/mL) before their use.
Immunoblot analyses
The SP and non-SP cell lysates were prepared as previously
described [36], [38], [60]. The protein concentrations were
estimated by using a detergent-compatible protein assay kit from
Bio-Rad Laboratories, Inc. (Hercules, CA). The samples corre-
sponding to 20 mg proteins were resolved by electrophoresis on a 8
or 10% SDS-polyacrylamide gel under reducing conditions. The
proteins were transferred onto an immobilon-P transfer membrane
and blocked in 5% non-fat dry milk in PBS for 2 h and subjected to
the standard immunodetection procedure. At the end of incubation,
the blot was washed in TBST (50 mM Tris-HCl, pH 7.4, 150 mM
NaCl and 0.05% Tween) and incubated with horseradish peroxi-
dase-conjugated secondary antibody (Amersham Biosciences, Piscat-
away, NJ) for 1 h. Antibody-antigen complexes were visualized using
enhanced chemiluminescence kit (Amersham Biosciences).
Confocal microscopy analyses
The SP and non-SP cell fractions from the WPE1-NB26 cell line
were grown at a low density on sterilized cover slips for 24 h,
washed with PBS, and fixed in ice-cold methanol at 220uC for
2 min [36], [38], [52]. The cells were blocked in 10% goat serum
for 30 min and incubated with phycoerythrin-conjugated mono-
clonal anti-CD133/2 antibody (293C3), mouse monoclonal anti-
CD44 (HCAM, F-4) antibody, rabbit polyclonal anti-ABCG2
antibody (B-25), rabbit polyclonal anti-EGFR antibody (1105), goat
polyclonal anti-Tyr1173-pEGFR antibody (1173), rabbit monoclonal
anti-pAkt antibody (D9E), rabbit polyclonal anti-NF-kB antibody
(C-20), rabbit polyclonal anti-MIC-1 antibody or mouse monoclo-
nal anti-b-actin antibody (clone AC-15) diluted in PBS for 1 h at
room temperature. After three washes with PBS, the cells were then
incubated with fluorescein isothiocyanate (FITC)-conjugated goat
anti-mouse, FITC-conjugated donkey anti-goat and/or Texas red-
conjugated goat anti-rabbit secondary antibody (Jackson Immuno-
Research Laboratories, Inc., West Grove, PA) for 1 h. In addition,
the SP cells treated with different cytotoxic agents during 4 days
were stained with MitoTracker Red CMXRos in humidified
chamber at 37uC in the dark for 30 min prior to the fixation and
staining of SP cells with mouse monoclonal anti-cytochrome c
antibody for 1 h followed by an incubation with FITC-conjugated
goat anti-mouse for 1 h. Then, all of PC cells were washed again
with PBS, nuclei counterstained with diamidino-2-phenylindole
(DAPI) and mounted on glass slides in anti-fade Vestashield
mounting medium (Vector Laboratories, Burlingame, CA). Immu-
nofluorescence staining was observed under a confocal laser
scanning microscope (LSM 410, Zeiss, Gottingen, Germany).
Prostasphere-forming and disintegration assays
The SP and non-SP cell fractions isolated from the highly
tumorigenic and invasive WPE1-NB26 cell mass were maintained in
serum-free keratinocyte culture medium. The self-renewal capacity of
SP cells versus the non-SP cell fraction isolated from the highly
tumorigenic and invasive WPE1-NB26 cell line was estimated by
their ability to form the non-adherent aggregates designated as
prostaspheres in serum-free culture conditions under ultra-low
attachment plate (Corning, invitrogen). For prostasphere-forming
assays, 500 viable SP or non-SP cells obtained after cell sorting were
suspended in serum free-keratinocyte medium without or with
exogenous EGF (10 ng/ml) onto a 6-well ultra-low attachment plate
in the absence or presence of different drugs. The tested drugs include
a specific inhibitory agent of EGFR (gefitinib), PI3K (LY294002),
pAkt (pAkt inhibitor VIII), NF-kB (partenolide) and MIC-1 (anti-
MIC-1 antibody) as well as the current chemotherapeutic drug
docetaxel. All samples were plated in triplicate. After 7 days of
incubation, the numbers of prostaspheres formed were counted and
the representative pictures of SP WPE1-NB26 cell-derived prosta-
spheres were photographed by using Accu-scope phase-contrast
microscope at a magnification of 2006.
In addition, for the disintegration assays, 500 viable SP WPE1-
NB26 cells were grown in serum-free culture conditions under an
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ultra-low attachment plate during 7 days for the formation of
prostaspheres and then the tested drugs were added to culture
medium and incubated for 4 additional days. At day 11, the
representative pictures of disintegrated prostaspheres were photo-
graphed by using Accu-scope phase-contrast microscope at a
magnification of 2006.
TUNEL assay
The terminal deoxynucleotidedyl transferase dUTP nick end
labeling (TUNEL) assay was performed to detect the DNA
fragmentation indicative of apoptotic cell death induced by tested
cytotoxic agents on the SP WPE1-NB26 cell subpopulation. After
washing of fixed SP WPE1-NB26 cells with PBS, cells were
incubated in the TdT reaction mixture consisting of nucleotide-
labelingmix (TUNELLabel) contains fluorescein-dUTP and -dNTPs
plus TdT enzyme (Roche diagnostics, IN) in humidified chamber at
37uC in the dark for 1 h. The SP cells were washed three times in
PBS and incubated with a primary antibody directed against the
cleaved capsase-9 fragment for 1 h at room temperature, followed by
an incubation with FTIC-conjugate secondary antibody for 1 h.
After three rinses with PBS, cells were counterstained with DAPI for
nuclear stain and visualized by confocal fluorescence microscopy as
above mentioned.
Cell viability assays
For cell viability assays, the SP and non-SP cell fractions isolated
from the WPE1-NB26 cell line were seeded on 96-well plates at a
density of 36104 cells per well in a total volume of 200 mL free-serum
keratinocyte culture medium as previously mentioned [36], [38], [52].
After 3 days, the SP and non-SP WPE1-NB26 cells were untreated or
treated with different concentrations of tested drugs including gefitinib,
LY294002, pAkt inhibitor VIII, partenolide, anti-MIC-1 antibody or
docetaxel, alone or in combination. After 72 hours of incubation, the
cell viability was estimated by a MTT colorimetric test.
Flow cytofluorometric analyses
SP WPE1-NB26 cells were grown at a density of 56105 cells on
25 cm2 dishes as described previously. The SP cells were treated
with different concentrations of tested drugs, alone or in
combination with 5 nM docetaxel during four days. The apoptotic
effect induced by tested agents on the SP WPE1-NB26 cells was
estimated after DNA staining of each sample with the propidium
iodide by FACS analyses as previously described [36], [38], [52].
Statistical analyses
Statistical analyses were performed using the Student’s t-test to
compare the results with P values,0.05 indicating statistically
significant differences. More specifically, immunohistochemical
data were analyzed using Windows version 9.6.4.0. software. The
composite scores of biomarker expression were considered as
continous variables and compared using Student’s two-tailed t test
assuming unequal variance for independent samples.
Results
Immunohistochemical analyses of expression levels of
EGFR, Ser473-pAkt, NF-kB p65 and MIC-1 signaling
elements in non-malignant and malignant prostate
tissue specimens
The results from immunohistochemical analyses have indicated a
very weak to undetectable immunostaining for EGFR, Ser473-pAkt,
NF-kB p65 and MIC-1 in normal prostatic tissues of biopsy and
adjacent non-malignant prostatic tissues from PC patients (Figure 1).
In contrast, an enhanced expression of all of these biomarkers was
detected in 66–75% of the 76 cases of prostatic adenocarcinomas
(Gleason scores=6–10) analyzed versus normal prostate tissues and
associatedwith the stages (T2–T4) of the disease progression (Table 1).
More particularly, a weak cytoplasmic and membrane immunostain-
ing for the EGFR protein were detected only in a small number of
basal and luminal prostatic epithelial cells in non-malignant prostatic
tissues while its expression varied from moderate to strong within the
cytoplasm and at the membrane respectively, in the malignant
epithelial cells localized in the intermediate and luminal compart-
ments in a subset of primary prostatic adenocarcinoma specimens
(Figure 1a). The staining intensity associated with the EGFR protein
expression was enhanced in 68% of 76 cases of primary prostatic
adenocarcinoma specimens analyzed, as compared with the normal
prostatic tissue from biopsy (Table 1). Moreover, the composite score
value obtained for EGFR expression in PC specimens (3.460.4) was
significantly superior to the value for normal prostate tissues
(0.460.2); *p,0.0001) (Figure 2a). As shown in Figure 1b and c,
the activated Ser473-pAkt phosphorylated form was also overex-
pressed in 66% of 76 cases of the prostatic adenocarcinomas analyzed
and detected in the cytoplasm in PC epithelial cells whereas an
enhanced expression of the p65 subunit NF-kB transcription factor
occurred in 75% of 76 cases of prostatic adenocarcinomas and was
mainly detected in cytoplasm and nuclei of PC epithelial cells. The
composite score values obtained for Ser473-pAkt and NF-kB p65
expression in PC specimens (3.360.4 and 2.760.3) were significantly
enhanced as compared to the value for normal prostate tissues
(0.360.1 and 0.360.2; p,0.0001), respectively (Figure 2b and c). In
addition, a stronger positive immunostaining was also seen for the
MIC-1 protein in the cytoplasm and near the membrane in PC
epithelial cells as well as for secreted MIC-1 in tumor stroma in 71%
of 76 cases of prostatic adenocarcinomas as compared to normal and
adjacent non-malignant prostate tissues analyzed (Figure 1d). The
composite score value obtained for MIC-1 expression in PC
specimens (3.760.4.) was significantly enhanced relative to the
value for normal prostate tissues (0.460.3; *p,0.0001) (Figure 2d).
Importantly, the results have also indicated that Ser473-pAkt, NF-kB
p65 and MIC-1 were co-expressed with EGFR in the same subset
corresponding at about 54–62% of PC tissue specimens analyzed
suggesting that these oncogenic signaling elements may all cooperate
to promote the malignant transformation of PC epithelial cells during
disease progression to a locally advanced disease state (Table 1).
Importantly, a positive immunostaining varying from moderate
to strong, within the cytoplasm and near the membrane or in
nuclei was also detected for EGFR, Ser473-pAkt, NF-kB p65 and
MIC-1 in PC cells in 80–100% of bone metastasis tissues analyzed
from 30 PC patients (Gleason scores = 6–10) (Figure 3; Table 1).
Moreover, MIC-1 immunostaining varied from very weak to
moderate intensity was seen in the stroma of PC bone metastasis
tissues (Figure 3d). The composite scores obtained for the
expression of all of these biomarkers in bone metastasis tissues
from PC patients were also superior to the values observed for
normal prostatic tissues and prostatic adenocarcinoma speciments
(Figure 2; *p,0.0001).
Double immunohistofluorescence confocal microscopy
analyses of the expression level of the CD133 stem cell-
like marker and its co-localization with EGFR, Ser473-pAkt,
NF-kB p65 and MIC-1 signaling elements in non-
malignant and malignant prostate tissue specimens
To obtain experimental evidence of the potential implication of
the enhanced expression and/or activation of EGFR, pAkt, NF-
kB p65 and MIC-1 in the malignant transformation of CD133+
Distinct Biomarkers and Targets in PC Cells
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31919
adult prostatic stem/progenitor cells into CD133+ PC stem/
progenitor cells, we have also characterized the co-localization of
the CD133 stem cell-like marker with these oncogenic signaling
elements in the non-malignant and malignant prostatic tissues
from patients (Figure 4). The results from double immunohisto-
fluorescence analyses have revealed that the expression levels of all
of these biomarkers were significantly enhanced in a small subset
of CD133+ PC cells dispersed through the intermediate compart-
ment in malignant prostate tissues as well as the bulk tumor mass
of CD1332 PC cells in prostatic adenocarcinomas relative to non-
malignant prostate tissue specimens from patients (Figure 4 and
Figure S1). More specifically, a positive immunoreactivity was
observed for EGFR and its phosphorylated Tyr1173-pEGFR
activated form, Ser473-pAkt and MIC-1 in the cytoplasm and
near or at the cell surface in intermediate and luminal PC cells
detected in prostatic adenocarcinoma specimens (Figure 4 and
Figure S1). Furthermore, a positive cytoplasmic and nuclear
staining was also detected in intermediate and luminal PC cells for
the NF-kB p65 subunit, which acts as a transcriptional signaling
effector of numerous growth factor cascades including the
activated EGFR pathway (Figure 4).
Western blot and immunofluorescence analyses of
expression levels of stem cell-like markers and EGFR,
Ser473-pAkt, NF-kB p65 and MIC-1 in SP and non-SP cell
fractions from parental WPE1-NB26 cell line
To further assess whether an enhanced expression and/or
activation of EGFR, PI3K/Akt, NF-kB and MIC-1 occur in PC
stem/progenitor cells during disease progression, a character-
ization of the expression levels of these signaling components
was performed using SP and non-SP cell fractions from highly
tumorigenic and invasive WPE1-NB26 cell line. The character-
ization of the parental WPE1-NB26 cell line by Hoechst dye
efflux technique has revealed the presence of a SP subpopulation
with a high Hoechst dye exclusion capacity corresponding to
about 0.61% of total WPE1-NB26 cell mass (Figure 5a).
Moreover, the FACS analyses after staining of WPE1-NB26
Figure 1. Immunohistochemical analyses of the expression levels of EGFR, Ser473-pAkt, NF-kB p65 and MIC-1 in non-malignant
prostate and prostatic adenocarcinoma tissues. Microarray sections of non-malignant and malignant prostate tissue specimens were probed
with an anti-EGFR, -Ser473-pAkt, -NF-kB p65 or -MIC-1 antibody after blocking with serum. All sections were examined under a microscope and the
immunoreactivity was judged by dark brown staining. Representative pictures of stained tissue specimens of normal prostate, non-malignant
adjacent tissues of prostatic tumor and prostatic adenocarcinoma obtained for (a) EGFR, (b) Ser473-pAkt, (c) NF-kB p65 and (d) MIC-1 are shown at
original magnifications of6100 and6400. The arrows indicate the localization of basal cells in normal and non-malignant prostate epithelium and
immunostaining detected for these biomarkers in prostatic adenocarcinoma tissue specimen. Moreover, the positive immunostaining detected for
secreted MIC-1 protein in the stromal compartment adjacent to prostatic tumor tissue is also indicated.
doi:10.1371/journal.pone.0031919.g001
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cells with phycoerythrin-labeled CD133 antibody has also
indicated the presence of a small WPE1-NB26 cell population
expressing a high level of CD133 stem cell-like marker
corresponding to about 0.60% of the total PC cell mass
(Figure 5b). The characterization of phenotypic features of the
SP cell subpopulation from parental WPE1-NB26 cells by
Western blot and immunofluorescence analyses has also
revealed that these immature cells expressed higher levels of
Figure 2. Comparison of the composite scores of expression levels of EGFR, Ser473-pAkt, NF-kB p65 and MIC-1 in non-malignant
and malignant tissues from PC patients. Box plots showing the expression levels of (a) EGFR, (b) Ser473-pAkt, (c) NF-kB p65 and (d) MIC-1 during
PC progression to metastatic disease stages. *, P,0.0001, indicates a significant increase between the composite scores obtained for prostatic
adenocarcinoma and PC bone metastasis specimens relative to composite scores obtained for normal prostatic tissues.
doi:10.1371/journal.pone.0031919.g002
Table 1. Immunohistochemical analyses of biomarker expression levels in prostate adenocarcinoma tissues and PC bone
metastasis specimens relative to normal prostate tissues.
Pathological diagnosis
aNumber of
cases
Positive staining
for EGFR
Positive staining
for Ser473-pAkt
Positive staining
for NF-kB p65
Positive staining
for MIC-1
Adenocarcinoma T2/42 cases 55% 62% 69% 71%
Adenocarcinoma T3/30 cases 83% 80% 80% 68%
Adenocarcinoma T4/4 cases 100% 100% 100% 100%
Adenocarcinoma T2-T4/Total: 76 cases 68% 66% 75% 71%
Adenocarcinoma T2-T4/Total:
76 cases
— 54% co-expressed
with EGFR
62% co-expressed
with EGFR
57% co-expressed
with EGFR
PC bone metastasis Total: 30 cases 93% 80% 93% 100%
aT-primary tumor: T2, tumor confined within prostate; T3, tumor extends through the prostate caspsule and T4, Tumor is fixed or invades adjacent structures other
than seminal vesicles.
doi:10.1371/journal.pone.0031919.t001
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Figure 3. Immunohistochemical analyses of the expression levels of EGFR, Ser473-pAkt, NF-kB p65 and MIC-1 in PC bone metastasis
tissues. Microarray sections of PC bone metastasis tissue specimens were probed with anti-EGFR, -Ser473-pAkt, -NF-kB p65 or -MIC-1 antibody after
blocking with serum. All sections were examined under a microscope and the immunoreactivity was judged by dark brown staining. Representative
pictures of stained PC bone tissue specimens obtained for EGFR, Ser473-pAkt, NF-kB p65 or MIC-1 are shown at original magnifications of6100 and
6400.
doi:10.1371/journal.pone.0031919.g003
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CD133 and CD44 stem cell-like markers and ABC multidrug
transporter ABCG2 relative to the non-SP WPE1-NB26 cell
fraction (Figure 5c and d). Importantly, the SP and non-SP
WPE1-NB26 cell fractions also expressed different drug
resistance-associated molecules, including EGFR, Ser473-pAkt,
NF-kB p65 and MIC-1 (Figure 5c and d).
Figure 4. Immunofluorescence analyses of expression levels of EGFR, Ser473-pAkt, NF-kB p65 and MIC-1 signaling elements and
their co-localization with a CD133 stem cell-like marker in non-malignant and malignant prostatic tissues. The double
immunofluorescence analyses of the co-localization of the expression of markers in normal prostate and prostatic adenocarcinoma specimens
from patients was simultaneously done with fluorescein-labeled anti-EGFR, -Ser473-pAkt, -NF-kB p65 or -MIC-1 antibody (green) plus phycoerythrin-
labeled anti-CD133 antibody (red) after blocking with goat serum as described in Materials and Methods. The arrows indicate a double staining
(yellow/purple) detected by confocal analyses, which is indicative of the co-localization of these markers. Representative pictures are shown at the
original magnification of6630.
doi:10.1371/journal.pone.0031919.g004
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Figure 5. Characterization of phenotypic features of SP and non-SP cell fractions from parental tumorigenic and invasive WPE1-
NB26 cells by the Hoechst dye efflux technique and FACS. a) Representative data of the Hoechst dye efflux profile obtained after staining of
parental WPE1-NB26 cell line with fluorescent Hoechst dye showing the SP cell subpopulation (green) and non-SP fraction (blue) detected in the total
mass of parental WPE1-NB26 cells. b) FACS profiles obtained after staining of parental WPE1-NB26 cells with phycoerythrin -labeled anti-CD133
antibody showing the percentage of CD133+ and CD1332 PC cells detected in the total mass of parental WPE1-NB26 cells. c) Comparative Western
blot analyses of expression levels of prostatic stem cell-like markers (CD133 and CD44), multidrug transporter ABCG2, EGFR, Ser473-pAkt, NF-kB p65
subunit and secreted MIC-1 proteins detected in the SP and non-SP cell fractions isolated from parental WPE1-NB26 cell line. d) Immunofluorescence
staining of methanol-fixed prostaspheres derived from SP cells and the adherent non-SP cell fraction isolated from the parental WPE1-NB26 cell line
were done with anti-EGFR plus Tyr1173-pEGFR, Ser473-pAkt, NF-kB p65 or MIC-1 primary antibody plus fluorescein (green) and/or Texas red secondary
antibody (red) and 49,6-diamidino-2-phenylindole (nuclear blue) after blocking with goat serum. Representative pictures showing the expression level
and cellular localization obtained for the stem cell-like markers including CD133 (red), CD44 (green) and ABCG2 (red) as well as overlaps of EGFR/
Tyr1173-pEGFR (red/green, hybrid yellow), Ser473-pAkt (red), NF-kB p65 (red) and MIC-1 (red) are shown at the original magnification of6630.
doi:10.1371/journal.pone.0031919.g005
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Determination of the functions of EGFR, PI3K/pAkt, NF-
kB and MIC-1 signaling elements for the self-renewal of
SP cells versus the non-SP cell fraction from WPE1-NB26
cell line
The establishment of the functions of EGFR, PI3K/pAkt, NF-
kB and MIC-1 for the self-renewal of the SP cell subpopulation
versus the non-SP cell fraction isolated from the highly tumorigenic
and invasive WPE1-NB26 cell line was done by performing
prostasphere-forming assays in the absence or presence of specific
inhibitory agents of these signaling elements in serum free-
keratinocyte medium under an ultra-low attachment plate. As
shown in Figure 6a, the results from prostasphere-forming assays
have revealed that the SP cells from the WPE1-NB26 cell line
were able to generate many dense prostaspheres with a large size
in culture after 7 days in the absence of EGF. Moreover, the
addition of exogenous EGF into culture medium significantly
promoted the number and size of prostaspheres formed by SP
WPE1-NB26 cells indicating an important role of EGF-EGFR
system for the self-renewal of these immature PC cells (Figure 6b).
In contrast, the non-SP WPE1-NB26 cell fraction after FAC
sorting formed only a small number of diffuse, abortive and very
small primary prostaspheres in the absence or presence of EGF,
while no secondary prostasphere was formed at the second passage
as compared to the high prostasphere-forming capacity of SP
WPE1-NB26 cells that was retained upon serial passage (Figure 6a
and b). We have also observed that the 10 ml/ml of the pre-
immune rabbit serum was used as control has not significant effect
on the prostasphere-forming ability of SP WPE1-NB26 cells as
compared to 10 ml/ml anti-MIC-1 antibody (data not shown).
Also, the treatment with docetaxel has not significant effect on the
prostasphere-forming ability of SP WPE1-NB26 cells in the
absence or presence of EGF (Figure 6a and b).
Importantly, the data have also indicated that the number and
size of the primary prostaspheres formed by CD133+ SP WPE1-
NB26 cells without (basal level) and with EGF were significantly
reduced in the presence of different concentrations of specific
inhibitory agents of EGFR (gefitinib), PI3K (LY294002), pAkt (Akt
inhibitor VIII), NF-kB (partenolide) or MIC-1 (anti-MIC-1
antibody) (Figure 6a, b and c). In particular, the prostasphere
numbers were reduced up at 70% in the presence of 5 mM
gefitinib, 10 mM LY294002, 10 mM Akt inhibitor VIII or 10 mM
partenolide and about 60% for 10 ml/ml of the anti-MIC-1
antibody, indicating that EGF/EGFR, PI3K/Akt, NF-kB and
MIC-1 signaling elements can contribute to the high self-renewal
capacity of SP WPE1-NB26 cells (Figure 6c).
Determination of the cytotoxic effects induced through
the inhibition of EGFR, PI3K/pAkt, NF-kB and MIC-1
signaling elements on SP cells versus the non-SP cell
fraction from WPE1-NB26 cell line
The results from MTT analyses have indicated that a treatment
with increasing concentrations of gefitinib, Akt inhibitor VIII,
partenolide or anti-MIC-1 antibody for 72 hours significantly
reduced the number of viable SP and non-SP WPE1-NB26 cells
(Figure 7). We have also observed that 10 ml/ml of the pre-
immune rabbit serum used as control has not significant effect on
the viability of cells as compared to 10 ml/ml anti-MIC-1 antibody
(data not shown). Moreover, a treatment with the current
chemotherapeutic drug docetaxel induced only a small cytotoxic
effect on the SP WPE1-NB26 cell fraction while it markedly
reduced the number of viable non-SP WPE1-NB26 cells (Figure 7).
As shown in Figure 8a, a treatment with gefitinib, LY294002, Akt
inhibitor VIII, partenolide or anti-MIC-1 antibody for 4 days was
also effective at inducing the disintegration of the dense prosta-
spheres generated by SP WPE1-NB26 cells after 7 days of cultures
under ultra-low attachment plate while docetaxel had no
significant effect (Figure 8a).
In addition, in order to further investigate whether the
suppression of EGFR, PI3K/pAkt, NF-kB, MIC-1 activity with
specific inhibitory agents induced the cytotoxic effects on SP cells
via a mitochondria- and caspase-dependent apoptotic pathway, the
double-staining of cytochrome c plus MitoTracker Red CMXRos
dye that specifically stains the mitochondria as well as the cleaved
caspase-9 fragment plus TUNEL were performed. The data of
double-immunofluorescence analyses of cellular localization of
cytochrome c and MitoTracker Red have indicated that the
cytotoxic effects induced by tested agents on SP WPE1-NB26 cells
were associated with a loss of mitochondrial transmembrane
potential (DYm depolarization) as visualized by a decrease of the
red staining for membrane potential sensitive dye, CMXRos in
treated SP cells as compared to untreated SP cells used as controls
(Figure 8b). The SP cells treated with tested cytotoxic agents also
showed a diffuse green staining for cytochome c indicative of the
release of cytochrome c from mitochondria into cytoplasm as
compared to untreated SP cells (Figure 8b). Furthermore, the
results of double-staining for the cleaved caspase-9 fragment and
TUNEL have also revealed that the cytotoxic effects induced by
tested agents was accompanied by an increase of the number of
cleaved caspase-9 fragment- and TUNEL-positive SP WPE1-
NB26 cells (Figure 8c). Together these date suggest that the tested
cytotoxic agents may induce the cytochrome c release from
mitochondria, caspase activation and DNA fragmentation in SP
WPE1-NB26 cells which may results into the apoptotic death of
some treated SP cells.
In support with this, the quantitative analyses of the number of
cells detected in the sub-G1 phase by FACS have indicated that
increasing concentrations of the tested drugs induced a high rate of
apoptotic death on SP WPE1-NB26 cells as compared to
untreated SP WPE1-NB26 used as control (Figure 9). Importantly,
a combination of 5 mM gefitinib, 10 mM LY294002, 10 mM Akt
inhibitor VIII, 10 mM partenolide or 10 ml/mL of anti-MIC-1
antibody with 5 nM docetaxel was also more effective than
individual drugs at inducing the apoptotic effects on SP WPE1-
NB26 cells (Figure 9). This indicates that these drugs can
sensibilize the immature and chemoresistant PC cells to the
cytotoxic effects of docetaxel.
Discussion
There has been significant improvement in the diagnosis of
early stage PCs by using a combination of screening tests including
digital rectal examination, the measurement of serum prostate-
specific antigen (PSA) in blood, histological analyses of the
expression levels of PC-specific biomarkers in transrectal ultra-
sound-guided needle biopsy of prostatic tissues and imaging and
genetic tests [6], [7], [62]–[65]. These screening tests have led to
the identification of previously undetected cases of PCs. In spite of
this important advancement, there remains a lack of accurate
sensibility and specificity of the current diagnostic and prognostic
biomarkers, including the PSA [6], [7], [63–66]. Combined with
the limited tissue samples available in core biopsy specimens and
heterogeneity of the disease, these factors underline the urgent
need to validate novel PC-specific biomarkers to optimize the
current detection tests and allow individualized treatment of PC
patients [3], [6], [7], [63]–[67]. More recently, the development of
different multiplex strategies by using new biomarkers such as a-
methyl CoA-racemase ‘‘AMACR’’, pAkt and p63 with the
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conventional histological markers, including high molecular
weight cytokeratin ‘‘34betaE12’’, has given promising results for
optimizing conventional screening tests and improving the
accuracy of diagnosis and prognosis of PC patients [68]–[71].
Data from immunhistochemical analyses in the present investiga-
tion have indicated that EGFR, pAkt, NF-kB p65 and MIC-1
were overexpressed in the same subset of localized PC tissue
specimens as compared to adjacent and normal prostatic tissues
during PC progression to locally advanced disease as well as in
bone metastasis specimens from PC patients (Figures 1, 2, 3;
Figure 6. Determination of the effects induced by different drugs on the prostasphere-forming ability of the SP cell fraction from
highly invasive and tumorigenic WPE1-NB26 cell line. The SP and non-SP cell fractions from the WPE1-NB26 cell line were subjected to the
prostasphere formation culture on an ultra-low attachment plate in serum-free keratinocyte medium. The representative pictures of the dense
prostaspheres formed by SP WPE1-NB26 cells (a) without or (b) after a treatment with exogenous EGF as compared to diffuse, abortive and very small
aggregates formed by non-SP WPE1-NB26 cells are shown at a similar magnification of 6200. Moreover, the representative pictures of the
prostaspheres formed by the SP WPE1-NB26 cell fraction (a) without or (b) after a treatment with exogenous EGF in the presence of different drugs,
including a specific inhibitory agent of EGFR (gefitinib), PI3K (LY294002), pAkt (pAkt inhibitor VIII), NF-kB (partenolide), MIC-1 (anti-MIC-1 antibody) or
docetaxel, are also shown at a similar magnification of6200. The quantitative data of the number of prostaspheres formed by the SP WPE1-NB26 cell
fraction (c) without or (d) after a treatment with exogenous EGF in the absence (control) or presence of different inhibitory agents obtained from at
least 3 separate experiments are shown.
doi:10.1371/journal.pone.0031919.g006
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Table 1). Moreover, the immunofluorescence analyses of these
distinct molecular biomarkers with the CD133 stem cell-like
marker have also indicated that these oncogenic products were
overexpressed in a small subset of CD133+ PC cells and the bulk
mass of CD1332 PC cells in prostatic adenocarcinoma specimens
relative to normal prostatic tissues (Figure 4 and Figure S1).
These data suggest the potential implication of these oncogenic
products in the malignant transformation of PC stem/progenitor
cells with stem cell-like features and their progenies in clinical
settings.
Accordingly to these results, prior studies have also indicated
that a progressive increase of the expression and/or activation of
the individual biomarker EGFR, pAkt, NF-kB p65 or MIC-1
often occurred in PC stem/progenitor cells and their progenies
during the PC progression to AI, invasive and metastatic disease
states [15], [16], [18]–[21], [23], [25]–[27], [30]–[39],[52]. The
enhanced expression of these oncogenic products was directly
associated with treatment resistance, disease recurrence and a
poor outcome and survival of PC patients [15], [16], [18]–[21],
[23], [25]–[27], [30]–[39], [52]. More specifically, the
Figure 7. Cytotoxic effects induced by different tested drugs on SP and non-SP cell fractions isolated from highly tumorigenic and
invasive WPE1-NB26 cells. The SP and non-SP WPE1-NB26 cell fractions were untreated or treated with the indicated concentrations of gefitinib,
LY294002, pAkt inhibitor VIII, partenolide, anti-MIC-1 antibody or docetaxel for 72 hours and the cell viability was analyzed by MTT tests. The data are
the means of at least three different experiments done in triplicate. *, P,0.05, indicates a significant difference between the cytotoxic effects induced
by individual drugs on the SP cells versus the non-SP WPE1-NB26 cell fraction.
doi:10.1371/journal.pone.0031919.g007
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characterization of PC cells and animal models relevant to
prostate carcinogenesis has indicated that the persistent activa-
tion of EGFR and PI3K/Akt in PC cells with stem cell-like
features may contribute to their high self-renewal and tumori-
genic capacities, treatment resistance and tumor re-growth [13]–
[15], [21], [58], [72]–[74]. It has also been shown that the
enhanced expression and constitutive activation of NF-kB, which
may be induced through diverse growth factor cascades,
including EGFR/PI3K/Akt and chemotherapeutic drugs such
as docetaxel in PC cells, may result in an increase of the
expression levels of numerous oncogenic products and anti-
apoptotic factors [22], [24]–[26], [30], [75], [76]. The gene
products induced via the NF-kB transcription factor include
MIC-1, interleukin-6, Bcl-2 and survivin that in turn may
promote the survival, invasion and chemoresistance of PC cells
[22], [24]–[26], [30], [75], [76]. Especially, a marked increase of
the MIC-1 level has been observed in PC cells and serum
samples during the early stage of prostate carcinogenesis and
transition from localized PCs to AI and metastatic disease states
[30], [31], [39], [77], [78]. The enhanced expression of MIC-1
was associated with the development of resistance to docetaxel
and mitoxantrone and a poor outcome and survival of the
patients [30], [31], [39], [77], [78]. Consequently, the combined
immunohistochemical analyses of EGFR, pAkt, NF-kB p65 and/
or MIC-1 expression levels with the current histological
biomarkers in the patient’s prostate biopsies could be helpful
in predicting the risk of PC progression to locally invasive and
metastatic stages, treatment resistance and biochemical disease
recurrence. A combination of these molecular biomarkers could
also be used to optimize the individualized treatment of PC
Figure 9. Quantitative analyses of apoptotic effects induced by different tested drugs, alone or in combination with docetaxel, on
SP cells isolated from highly tumorigenic and invasive WPE1-NB26 cells. The SP WPE1-NB26 cells were untreated or treated with the
indicated concentrations of a specific inhibitory agent including EGFR (gefitinib), PI3K (LY294002), pAkt (pAkt inhibitor VIII), NF-kB (partenolide) and
MIC-1 (anti-MIC-1 antibody), alone or in combination with 5 nM docetaxel for 4 days, and the apoptotic cell death was analyzed by FACS. The panel
shows the apoptotic effect induced by the tested agents that are expressed as the percentage of apoptotic SP WPE1-NB26 cells compared to non-
treated SP cells (control). *, P,0.05, indicates a significant difference between the apoptotic effect induced by tested drugs plus 5 nM docetaxel
versus individual drugs on the SP WPE1-NB26 cell fraction.
doi:10.1371/journal.pone.0031919.g009
Figure 8. Estimation of the disintegration effects induced by different tested drugs on prostaspheres derived from SP WPE1-NB26
cell-and implication of the mitochondrial and caspase pathways. a) Representative pictures of the disintegration effect induced by a
treatment with tested drugs during 4 days on the prostaspheres derived from SP WPE1-NB26 cells. b) Immunofluorescence staining of SP WPE1-NB26
cells after a treatment with indicated cytotoxic agents was done with anti-cytochrome c primary antibody plus fluorescein (green) secondary
antibody and the mitochondria and nuclei stained with MitoTracker Red CMXRos (red) and DAPI (blue), respectively. Representative pictures showing
the expression level and cellular localization of mitochondria (red), cytochrome c in mitochondria (green/red; hybrid yellow) or cytoplasm (diffuse
green staining) are shown at the original magnification of 6630. c) Immunofluorescence staining of SP WPE1-NB26 cells after a treatment with
indicated cytotoxic agents was done with a primary antibody directed against the cleaved caspase-9 fragment plus Texas red secondary antibody
and TUNEL reactive mixture (green) and the nuclei counterstained with DAPI (blue). Representative pictures showing the expression level and cellular
localization of the cleaved caspase-9 fragment (red) and TUNEL and DAPI (green/blue; hybrid cyan) in SP WPE1-NB26 cells are shown at original
magnification6630. The overlaps of double nuclear staining with TUNEL and DAPI (green/blue; hybrid cyan) associated with DNA fragmentation
which is indicative of the apoptotic nuclei in SP cells are indicated by arrows. d) The SP WPE1-NB26 cells were untreated or treated with the indicated
concentrations of a specific inhibitory agent including EGFR (gefitinib), PI3K (LY294002), pAkt (pAkt inhibitor VIII), NF-kB (partenolide) and MIC-1 (anti-
MIC-1 antibody), alone or in combination with 5 nM docetaxel for 4 days, and the apoptotic cell death was analyzed by FACS. The panel shows the
apoptotic effect induced by the tested agents that are expressed as the percentage of apoptotic SP WPE1-NB26 cells compared to non-treated SP
cells (control). *, P,0.05, indicates a significant difference between the apoptotic effect induced by tested drugs plus 5 nM docetaxel versus
individual drugs on the SP WPE1-NB26 cell fraction.
doi:10.1371/journal.pone.0031919.g008
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patients that are susceptible to respond to the cytotoxic agents
targeting these oncogenic products.
In addition, the results of the present investigation have also
revealed that the targeting EGFR, PI3K/Akt, NF-kB or MIC-1 by
using gefitinib, LY294002/Akt inhibitor VIII, partenolide or anti-
MIC-1 antibody significantly inhibited the basal and EGF-
promoted prostasphere formation by CD133+ SP WPE1-NB26
cells endowed with stem cell-like features (Figures 5 and 6). These
data suggest that these oncogenic products may contribute to the
self-renewal capacity of CD133+ SP WPE1-NB26 cells. In
particular, the data have indicated that a treatment with
exogenous EGF of CD133+ SP WPE1-NB26 cells significantly
enhanced their prostasphere-forming ability at least in part
through the stimulation of PI3K/Akt and NF-kB/MIC-1
suggesting that EGF/EGFR system can provide important
functions for the high self-renewal ability of these immature PC
cells (Figure 6). Of therapeutic interest, all of tested pharmaco-
logical agents, including gefitinib, LY294002/Akt inhibitor VIII,
partenolide or anti-MIC-1 antibody, were also effective at
reducing the viability of SP and non-SP WPE1-NB26 cell fractions
(Figure 7). Importantly, all of these cytotoxic agents also induced
the disintegration of CD133+ SP WPE1-NB26 cell-derived
prostaspheres and apoptotic effects through the caspase activation,
and sensibilized these chemoresistant SP cells to apoptotic effects
induced by the current chemotherapeutic drug, docetaxel
(Figures 8 and 9). Collectively, these results support the clinical
relevance to use a combination of these distinct oncogenic
products as molecular targets to develop a multitargeted therapy
for eradicating the total PC cell mass. Consistent with this, our
recent works combined with several prior studies have revealed
that the down-regulation of the expression and/or activity of
EGFR, PI3K/Akt, NF-kB or MIC-1 signaling element resulted in
growth inhibition and a high rate of apoptotic death of androgen-
dependent, AI and metastatic PC cell lines, including PC stem/
progenitor cells [34], [36], [38], [58], [75], [76], [79], [80]. More
specifically, we have shown that the co-targeting of EGFR and
sonic hedgehog pathways by using gefitinib and cyclopamine with
the chemotherapeutic drug, docetaxel or mitoxantrone resulted in
supra-additive anti-proliferative, anti-invasive and apoptotic effects
on diverse invasive and metastatic PC cell lines, including CD133+
SP WPE1-NB26 cells, as compared to individual agents and two-
drug combinations [36], [52], [79]. Moreover, the inhibition of
PI3K/Akt/mTOR signaling elements by using a specific inhibitor
of PI3K (LY294002), mTOR (rapamycin, RAD-001 (40-O-(2-
hydroxyethyl)-rapamycin or CCl-779) or dual PI3K/mTOR
inhibitor (PI-103 or NVP-BEZ235) has also been observed to
induce a growth inhibition and cytotoxic effects on the CD133+/
CD44+ cell fraction and the bulk PC cell mass detected by
cytometric analyses [74]. It has also been reported that a treatment
with the sesquiterpene lactone, partenolide, of parental and
CD44high and CD442/low PC cell fractions isolated from
metastatic cell lines (DU145, PC3, VCAP and LAPC4) and
primary PC tumor cells induced cytotoxic effects in vitro through an
inhibition of NF-kB and Src-related signaling components and
inhibited the tumor growth of CD44high DU145 cell xenograft
models in vivo [80]. Importantly, the natural compound parteno-
lide was also effective at inducing the cytotoxic effects on CD133+
primary prostate tumor cells while CD133+ normal cells from
benign prostate hyperplasia were insensitive to this treatment type
in vitro [58].
Taken together, these observations suggest that the combined
histological analyses of the expression levels of EGFR, pAkt, NF-
kB p65 and/or MIC-1 with the current molecular biomarkers
used clinically may constitute a promising strategy to optimize the
efficacy of diagnosis, prediction of prognosis, long-term follow-up
and choice of therapeutic treatment of PC patients. These data
also support the therapeutic interest in using the specific inhibitory
agents of EGFR, PI3K/pAkt, NF-kB and/or MIC-1 for
eradicating PC stem/progenitor cells and their progenies, and
thereby improving the anticarcinogenic efficacy of current anti-
hormonal and first-line docetaxel-based chemotherapeutic regi-
mens against locally invasive and metastatic CRPCs and
preventing the disease relapse and the death of patients.
Supporting Information
Figure S1 Immunofluorescence analyses of expression
levels of activated Tyr1173-pEGFR signaling element and
its co-localization with a CD133 stem cell-like marker in
non-malignant and malignant prostatic tissues. The
double immunofluorescence analyses of the co-localization of the
expression of markers in normal prostate and prostatic adenocar-
cinoma specimens from patients was simultaneously done with
fluorescein-labeled anti-Tyr1173-pEGFR (green) plus phycoery-
thrin-labeled anti-CD133 antibody (red) after blocking with goat
serum as described in Materials and Methods. The arrows indicate
a double staining (yellow/purple) detected by confocal analyses,
which is indicative of the co-localization of these markers.
Representative pictures are shown at the original magnification
of6630.
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